NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $20.76 +0.25 (+1.22%) Closing price 04:00 PM EasternExtended Trading$20.80 +0.04 (+0.19%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bright Minds Biosciences Stock (NASDAQ:DRUG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DRUG alerts:Sign Up Key Stats Today's Range$20.20▼$21.8950-Day Range$18.93▼$65.0052-Week Range$17.40▼$123.75Volume135,111 shsAverage Volume291,803 shsMarket Capitalization$201.99 millionP/E RatioN/ADividend YieldN/APrice Target$126.29Consensus RatingModerate Buy Company Overview Bright Minds Biosciences is a clinical-stage biotechnology company developing medicines for neurological and psychiatric disorders. Its research focuses on compounds that act on serotonin receptors, which play a role in regulating brain activity. The company’s development programs include BMB-101, a serotonin 5-HT2C receptor agonist being investigated for seizure disorders. Bright Minds is developing its candidates as potential treatments; it does not market approved products.AI Generated. May Contain Errors. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreDRUG MarketRank™: 2.283453826215 of 5 starsBright Minds Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 699th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingBright Minds Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialBright Minds Biosciences has a consensus price target of $126.29, representing about 508.3% upside from its current price of $20.76.Amount of Analyst CoverageBright Minds Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($2.93) to ($6.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -9.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -9.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.36% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 7.91.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 3.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Bright Minds Biosciences this week, compared to 3 articles on an average week.Search Interest2 people have searched for DRUG on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRUG Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bright Minds Bioscience Inc. - DRUGNovember 17 at 5:51 PM | globenewswire.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsNovember 13, 2026 | americanbankingnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 18 at 1:00 AM | Porter & Company (Ad)Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & KorsinskyNovember 9, 2026 | prnewswire.comLevi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Bright Minds Biosciences (DRUG)November 5, 2026 | globenewswire.comBright Minds Biosciences: Promising Catalysts Despite The FDA SetbackNovember 5, 2026 | seekingalpha.comFDA puts partial hold on Bright Minds’ Phase II seizure studyNovember 3, 2026 | msn.comBright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWSNovember 3, 2026 | seekingalpha.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $78.04 at the beginning of the year. Since then, DRUG shares have decreased by 73.4% and is now trading at $20.76. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its quarterly earnings data on Friday, August, 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $1.05. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences shares reverse split on the morning of Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are Bright Minds Biosciences' major shareholders? Top institutional shareholders of Bright Minds Biosciences include Goldman Sachs Group Inc. (1.39%), State Street Corp (1.26%), B Group Inc. (0.98%) and Aquatic Capital Management LLC (0.05%). View institutional ownership trends. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include NVIDIA (NVDA), Rigetti Computing (RGTI), Archer Aviation (ACHR), IonQ (IONQ), SoundHound AI (SOUN), Tesla (TSLA) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/14/2026Today11/18/2026Next Earnings (Estimated)12/22/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, DRUG's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployees25Year Founded2019Price Target and Rating Average Price Target for Bright Minds Biosciences$126.29 High Price Target$220.00 Low Price Target$37.00 Potential Upside/Downside+508.3%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-12.46% Return on Assets-12.30% Debt Debt-to-Equity RatioN/A Current Ratio122.00 Quick Ratio122.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book2.49Miscellaneous Outstanding Shares9,730,000Free Float5,580,000Market Cap$201.99 million OptionableOptionable Beta-5.11 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:DRUG) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.